Boston Scientific Complaint-Handling Integration “No Small Task” – Attorney
This article was originally published in The Gray Sheet
Executive Summary
With new complaint management and tracking procedures in place, Boston Scientific now faces the large and costly task of fully implementing the system in time for a summer re-inspection by FDA, according to Jeffrey Gibbs, an attorney with the Washington, D.C. law firm Hyman, Phelps & McNamara
You may also be interested in...
Warning Letter Should Not Hinder Taxus Liberté Approval – Boston Scientific
Boston Scientific estimates it will be ready by June for FDA to re-inspect its facilities to confirm that the quality-control problems cited in a sweeping Jan. 25 warning letter have been fixed
Boston Scientific Stung With Across-The-Board Corporate Warning Letter
FDA is targeting Boston Scientific with a rare and far-reaching enforcement measure that could prevent some of the firm's investigational products from receiving market approval in the near term
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”